Unequal access to the COVID-19 vaccine fuelled calls for a patent waiver, but any major change needs to ensure a better outcome for developing economies.
It’s almost comically hypocritical to argue that the Therapeutic Goods Administration needs to ‘loosen up’ in the context of the COVID-19 pandemic.
We can do more in pursuing a zero-waste strategy in relation to sought-after COVID-19 vaccines.
For only the second time in 60 years, a drug has been approved for the treatment of lupus, a debilitating form of rheumatic disease.
Australia’s COVID-19 vaccine rollout priority should move from those most at risk of the disease to those most likely to spread it, according to new modelling.
There are three measures for assessing whether public policy is successful, and the Coalition has been found wanting on all three. But there’s one policy area that’s an even bigger disaster.
Unless vaccination rates pick up, Victoria’s snap five-day lockdown is unlikely to be enough to get on top of the infectious Delta variant.
The case is growing stronger for COVID-19 vaccine mixing-and-matching, with recent data showing high efficacy and protection against SARS-CoV-2 virus strains.
Inconsistency, uncertainty and confusion are leading to vaccination delays.
We need to fix our COVID-19 and vaccine rollout interpreting services – and translated information – so vulnerable pockets of our diverse population aren’t forgotten.
Supply isn’t the problem with the COVID-19 vaccination rollout – it’s the structural and communications issues that need addressing.
The rare blood-clotting issues associated with the Astra-Zeneca vaccine have recently made headlines, but it's too early to say whether it will increase overall vaccine hesitancy.
Pharmacy students are underlining their value by taking their skills from the classroom to the COVID-19 frontline.
Scientists are well-advanced in mapping the way forward to develop and repurpose medicines for respiratory virus patients in the post-COVID era.
Dr Harry Al-Wassiti, Research Fellow at the Monash Institute of Pharmaceutical Sciences (MIPS), answers the questions about the jab that's on everyone's mind.
The successful uptake of Australia’s COVID program hinges on tailored communication campaigns that appeal to all sectors of the community.
Unprecedented efforts are driving the global push for a safe and effective COVID-19 vaccine. Here's how it's likely to be rolled out in Australia.
Dummy text
